A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma

Trial Profile

A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs TK 216 (Primary)
  • Indications Ewing's sarcoma
  • Focus Adverse reactions; First in man
  • Sponsors Oncternal Therapeutics, Inc.; Tokalas, Inc.
  • Most Recent Events

    • 20 Oct 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
    • 20 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.
    • 02 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, nine patients have been enrolled till date.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top